Black Titan (BTTC) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Molecular Partners is the larger company by market cap ($145.9 million vs $6.8 million), about 21.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | BTTC | MOLN |
|---|---|---|
| Share price | $0.495 | $3.81 |
| Market cap | $6.78M | $145.94M |
| 1-day change | -3.51% | 0.00% |
| YTD return | — | -12.59% |
| 1-year return | — | -2.06% |
| 5-year return | — | -80.76% |
| EPS (TTM) | $-0.46 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.05 | $5.36 |
| 52-week low | $0.342 | $3.53 |
| Distance from 52-week high | -95.07% | -28.92% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +172.18% |
| Average volume | 11.84M | 1.15K |
| Shares outstanding | 13.70M | 38.31M |
| Employees | — | 134 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Molecular Partners is about 21.5 times larger than Black Titan by market value ($145.94M vs $6.78M).
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
BTTC vs MOLN FAQ
Which is bigger, Black Titan or Molecular Partners?
Molecular Partners (MOLN) is larger, with a market capitalization of $145.94M compared with $6.78M for Black Titan (BTTC).
Are Black Titan and Molecular Partners in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.